Mi-Prostate Score test improves on PSA for predicting cancer
More than 1 million men will undergo a prostate biopsy this year, but only about one-fifth of those biopsies will result in a cancer diagnosis.
The reason is that the traditional prostate cancer screening test – a blood test to measure prostate specific antigen, or PSA – does not give doctors a complete picture.
Now, the University of Michigan Health System has begun offering a new urine test called Mi-Prostate Score to improve on PSA screening for prostate cancer. The test incorporates three specific markers that could indicate cancer and studies have shown that the combination is far more accurate than PSA alone.
“Many more men have elevated PSA than actually have cancer but it can be difficult to determine this without biopsy. We need new tools to help patients and doctors make better decisions about what to do if serum PSA is elevated. Mi-Prostate Score helps with this,” says Scott Tomlins, M.D., Ph.D., assistant professor of pathology and urology at the University of Michigan.
Researchers validated the new test on nearly 2,000 urine samples. Mi-Prostate Score, or MiPS, was significantly more accurate than PSA alone for predicting cancer as well as predicting aggressive prostate cancer that is likely to grow and spread quickly.
Mi-Prostate Score developed from a discovery in the lab of Arul Chinnaiyan, M.D., Ph.D., in 2005 of a genetic anomaly that occurs in about half of all prostate cancers, an instance of two genes changing places and fusing together.
This gene fusion, T2:ERG, is believed to cause prostate cancer. Studies in prostate tissues show that the gene fusion almost always indicates cancer.
The new urine test looks for the T2:ERG fusion as well as another marker, PCA3. This is combined with serum PSA measure to produce a risk assessment for prostate cancer. The test also predicts risk for having an aggressive tumor, helping doctors and patients make decisions about whether to wait and monitor test levels or pursue immediate biopsy.
“This combination test is not designed to say definitively at diagnosis whether a man has aggressive prostate cancer, but it can provide a more accurate estimate of the likelihood of having cancer and the likelihood of that cancer being aggressive,” Tomlins says.
The Latest Bing News on:
- An Embarrassment of Riches in First-Line Treatment of Metastatic Hormone-Sensitive Prostate Canceron July 11, 2020 at 4:46 am
To address this challenge, an article in the 2020 ASCO Educational Book seeks to provide a data-driven and pragmatic framework to support oncologists in these high-stakes discussions with men ...
- Largest-Ever Study of Prostate Cancer Genomics in Black Men IDs Potential Targets for Precision Therapieson July 10, 2020 at 7:03 am
None of the individual tumor genetic differences that were identified are likely to explain significant differences in health outcomes or to prevent Black Americans from benefiting from a new ...
- The prognostic value of pain in castration-sensitive prostate canceron July 10, 2020 at 6:45 am
Cancer-related pain, usually associated with bone metastases, is a frequent and debilitating morbidity in patients with prostate cancer. To date there are only limited data regarding the prognostic ...
- Does Obesity Reduce Drug Efficacy in Breast Cancer?on July 10, 2020 at 6:08 am
Poor survival outcomes occurred among overweight patients treated with docetaxel-based adjuvant chemotherapy compared with peers given a non-taxane-based regimen.
- Karen Autio, MD, MSc, on Potential Role of CPIs in Prostate Canceron July 9, 2020 at 1:37 pm
In the following interview, Karen A. Autio, MD, MSc, of Memorial Sloan-Kettering Cancer Center in New York City, answered questions about the review, which was titled "Immune Checkpoint Blockade for ...
- The deleterious association between proton pump inhibitors and prostate cancer-specific mortality – a population-based cohort studyon July 8, 2020 at 8:30 am
Proton pump inhibitors (PPIs) are commonly prescribed medications that have been shown to have contradicting effects on cancer. We aimed to investigate the effect of pantoprazole and other PPIs on p ...
- Blood test can guide treatment for most aggressive prostate canceron July 7, 2020 at 6:30 am
Scientists have developed a simple blood test that can show which men with the most aggressive type of prostate cancer should respond to conventional therapy, and those who need other options.
- New technique to sort out complex interactions unique to prostate cancer cellson July 6, 2020 at 11:02 pm
UT Southwestern researchers have identified vast webs of small snippets of the genome that interact with each other and with genes to promote prostate cancer.
- A different Chia-PET provides insight into prostate canceron July 6, 2020 at 1:46 pm
UT Southwestern researchers have identified vast webs of small snippets of the genome that interact with each other and with genes to promote prostate cancer. Their findings, published June 22 in ...
- Dr. David Samadi from RoboticOncology voices concerns of COVID-19′s impact on prostate cancer screeningson July 3, 2020 at 6:15 am
In my years as a urologist and prostate cancer surgeon, I’ve never been more concerned for my patients than now,” exclaimed Dr. David Samadi, Director of Men’s Health and ...
The Latest Google Headlines on:
The Latest Bing News on:
Prostate cancer screening
- Alicia Morgans, MD, on Treatment Options for Metastatic Castration-Sensitive Prostate Canceron July 8, 2020 at 1:34 pm
Writing in this year's ASCO Educational Book, Alicia Morgans, MD, of Northwestern Medicine Feinberg School of Medicine in Chicago, discussed the many treatment options for men with newly diagnosed ...
- Ethnic variation in prostate cancer detection: a feasibility study for use of the Stockholm3 test in a multiethnic U.S. cohorton July 8, 2020 at 9:37 am
Urology. 2018;117:108–14. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for ...
- Sex differences in SARS-CoV-2 infection rates and the potential link to prostate canceron July 8, 2020 at 2:30 am
Dimple Chakravarty et al. review the rapidly emerging data indicating a higher rate of SARS-CoV-2 infection in men. They note that men in the age group most at risk of infection are also at high risk ...
- As it seeks prostate cancer drug approval, Peninsula drug maker targets a forgotten market: Black menon July 6, 2020 at 4:12 pm
So when Myovant Sciences Ltd. reached out to Ware's organization, BlackDoctor.org, with the idea of forming a coalition to not only reach out to educate men about prostate health ...
- Dr. David Samadi from RoboticOncology voices concerns of COVID-19's impact on prostate cancer screeningson July 3, 2020 at 6:27 am
A concerning fallout from the March COVID-19 shutdown has been the disastrous drop in cancer screenings. This worrisome discovery is according to a study in May by Epic Health Research Network. A ...
- Cancer treatment machine installed despite pandemicon July 1, 2020 at 11:00 pm
The first patient treated on Palmerston North Hospital’s new linear accelerator cancer treatment machine was a guest at the delayed formal opening of the facility. Patient Brian Jackson and wife ...
- Australian cancer testing declines during coronavirus pandemicon June 30, 2020 at 11:02 pm
The lack of personal protective equipment in hospitals and shortages of masks, gloves and sanitiser available to the public have forced many people to put off appointments.
- New Focus on ADT in Prostate Cancer Guidelineon June 30, 2020 at 1:39 pm
The new American Urological Association (AUA) guideline provides direction for the use of hormonal therapy (or androgen-deprivation therapy, ADT) for men with multiple categories of advanced and ...
- Tel Aviv-based Ibex to provide AI cancer diagnosis support to UK's NHSon June 30, 2020 at 12:23 pm
Cancer diagnosis in Britain's National Health Service is set to get an AI upgrade, thanks to a Tel Aviv based Ibex Medical Analytics. On Tuesday, Ibex announced its involvement in the UK's first ...
- Free cancer risk screening expanded in North Alabamaon June 30, 2020 at 10:07 am
The HudsonAlpha Institute for Biotechnology is expanding a genetic screening for cancer risk to five Alabama counties ...